WO2016020828A1 - Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies - Google Patents

Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies Download PDF

Info

Publication number
WO2016020828A1
WO2016020828A1 PCT/IB2015/055885 IB2015055885W WO2016020828A1 WO 2016020828 A1 WO2016020828 A1 WO 2016020828A1 IB 2015055885 W IB2015055885 W IB 2015055885W WO 2016020828 A1 WO2016020828 A1 WO 2016020828A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
acid
present
comprised
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/055885
Other languages
English (en)
French (fr)
Inventor
Raffaele Migliaccio
Antonella SARDEI
Carmela MIGLIACCIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES15754028T priority Critical patent/ES2976095T3/es
Priority to FIEP15754028.7T priority patent/FI3177281T3/fi
Priority to US15/502,316 priority patent/US9962355B2/en
Priority to DK15754028.7T priority patent/DK3177281T3/da
Priority to BR112017002474-8A priority patent/BR112017002474B1/pt
Priority to CA2957700A priority patent/CA2957700C/en
Priority to JP2017508099A priority patent/JP7118642B2/ja
Priority to CN201580042308.5A priority patent/CN106714792A/zh
Application filed by Individual filed Critical Individual
Priority to EP15754028.7A priority patent/EP3177281B1/en
Publication of WO2016020828A1 publication Critical patent/WO2016020828A1/en
Priority to IL250271A priority patent/IL250271B2/en
Priority to CONC2017/0001088A priority patent/CO2017001088A2/es
Anticipated expiration legal-status Critical
Priority to US15/946,950 priority patent/US10149827B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • a further object of the present invention is a pharmaceutical composition comprising the aforesaid mixture and at least one pharmaceutically acceptable excipient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/IB2015/055885 2014-08-08 2015-08-03 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies Ceased WO2016020828A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2017508099A JP7118642B2 (ja) 2014-08-08 2015-08-03 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
US15/502,316 US9962355B2 (en) 2014-08-08 2015-08-03 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
DK15754028.7T DK3177281T3 (da) 2014-08-08 2015-08-03 Blanding af fedtsyrer og palmitoylethanolamid til brug i behandlingen af betændelses og allergiske patologier
BR112017002474-8A BR112017002474B1 (pt) 2014-08-08 2015-08-03 Mistura contendo ácido graxo e palmitoiletanolamida e composição compreendendo tal mistura
CA2957700A CA2957700C (en) 2014-08-08 2015-08-03 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies.
CN201580042308.5A CN106714792A (zh) 2014-08-08 2015-08-03 用于治疗炎症性和过敏性病理学的脂肪酸和十六酰胺乙醇的混合物
EP15754028.7A EP3177281B1 (en) 2014-08-08 2015-08-03 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
ES15754028T ES2976095T3 (es) 2014-08-08 2015-08-03 Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
FIEP15754028.7T FI3177281T3 (fi) 2014-08-08 2015-08-03 Rasvahappojen ja palmitoyylietanoliamidin seos käytettäväksi tulehduksellisten ja allergisten patologioiden hoitoon
IL250271A IL250271B2 (en) 2014-08-08 2017-01-25 A mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
CONC2017/0001088A CO2017001088A2 (es) 2014-08-08 2017-02-06 Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
US15/946,950 US10149827B2 (en) 2014-08-08 2018-04-06 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141474 2014-08-08
ITMI2014A001474 2014-08-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/502,316 A-371-Of-International US9962355B2 (en) 2014-08-08 2015-08-03 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
US15/946,950 Continuation US10149827B2 (en) 2014-08-08 2018-04-06 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies

Publications (1)

Publication Number Publication Date
WO2016020828A1 true WO2016020828A1 (en) 2016-02-11

Family

ID=51663273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/055885 Ceased WO2016020828A1 (en) 2014-08-08 2015-08-03 Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies

Country Status (13)

Country Link
US (2) US9962355B2 (enExample)
EP (1) EP3177281B1 (enExample)
JP (3) JP7118642B2 (enExample)
CN (1) CN106714792A (enExample)
CA (1) CA2957700C (enExample)
CO (1) CO2017001088A2 (enExample)
DK (1) DK3177281T3 (enExample)
ES (1) ES2976095T3 (enExample)
FI (1) FI3177281T3 (enExample)
IL (1) IL250271B2 (enExample)
MA (1) MA40417A (enExample)
TW (1) TWI727926B (enExample)
WO (1) WO2016020828A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100024464A1 (it) * 2021-09-23 2023-03-23 Epitech Group S P A N-palmitoil-etanolamide e acido docosaesaenoico per l’uso nel trattamento del disturbo dello spettro autistico e di altre sindromi depressive

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100407A1 (en) * 2015-10-07 2017-04-13 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN109893520A (zh) * 2019-03-21 2019-06-18 中国科学院水生生物研究所 螺旋藻γ-亚麻酸的新用途
CA3136124C (en) * 2019-04-15 2024-04-09 Metagenics, Inc. Novel hemp and pea formulation and its use
WO2022061234A2 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Immunological effects of metabolites
CN114209683A (zh) * 2021-12-22 2022-03-22 中南大学湘雅三医院 壬二酸在制备治疗炎症性肠病药物中的应用
AU2022447402A1 (en) 2022-03-14 2024-08-29 Fera Diagnostics And Biologicals Corp. Fatty acid compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
WO2001024645A1 (en) * 1999-10-07 2001-04-12 Societe Des Produits Nestle S.A. Nutritional composition
WO2002053108A2 (en) * 2000-12-28 2002-07-11 Unilever Plc Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package
DE10217131A1 (de) * 2001-07-31 2003-02-13 Kuhs Kosmetik Gmbh & Co Kg Topisch applizierbare Zusammensetzung sowie Werkstoffgemisch
EP1844784A1 (en) * 2006-03-28 2007-10-17 Epitech Group S.r.l. A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
WO2008075978A2 (en) * 2006-12-20 2008-06-26 Seperex Nutritionals Limited An extract
WO2014135529A1 (en) * 2013-03-08 2014-09-12 Again Life Italia Srl Mixture of fatty acids for use in the treatment of inflammatory pathologies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
IT1257697B (it) * 1992-04-24 1996-02-01 Lifegroup Spa N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
ES2145052T3 (es) * 1992-06-19 2000-07-01 Univ California Lipidos para la humidificacion epidermica y la reparacion de la funcion de barrera.
EP0620000A3 (de) * 1992-12-18 1994-11-02 Rhone-Poulenc Rorer Gmbh Kosmetische und/oder pharmazeutische Verwendung von N-Acylalkanolaminen
US5599548A (en) * 1995-05-08 1997-02-04 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides and retinol or retinyl ester
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
JP2000159668A (ja) * 1998-11-26 2000-06-13 Nof Corp サイトカイン抑制剤
JP2000191525A (ja) * 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU2009215430B2 (en) * 2008-02-22 2015-02-12 Rigel Pharmaceuticals, Inc. Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
DE202008007621U1 (de) * 2008-06-04 2008-11-06 Zimmer, Bruno Kosmetisches und Nahrungsmittel aus unterschiedlichen Fettsäuren
JP2013521302A (ja) * 2010-03-02 2013-06-10 イマジネティクス，インコーポレイテッド ミリスチン酸を含む組成物およびその使用
ES2562419T3 (es) * 2010-04-13 2016-03-04 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos
ITMI20111284A1 (it) * 2011-07-11 2013-01-12 Giovanni Nusca Composizione farmaceutica.
EP2850062B1 (en) * 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
CN103242262A (zh) * 2013-05-24 2013-08-14 厦门大学 N-脂肪酰基乙醇胺水解酶抑制剂及其合成方法和用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
WO2001024645A1 (en) * 1999-10-07 2001-04-12 Societe Des Produits Nestle S.A. Nutritional composition
WO2002053108A2 (en) * 2000-12-28 2002-07-11 Unilever Plc Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package
DE10217131A1 (de) * 2001-07-31 2003-02-13 Kuhs Kosmetik Gmbh & Co Kg Topisch applizierbare Zusammensetzung sowie Werkstoffgemisch
EP1844784A1 (en) * 2006-03-28 2007-10-17 Epitech Group S.r.l. A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
WO2008075978A2 (en) * 2006-12-20 2008-06-26 Seperex Nutritionals Limited An extract
WO2014135529A1 (en) * 2013-03-08 2014-09-12 Again Life Italia Srl Mixture of fatty acids for use in the treatment of inflammatory pathologies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 2009
ANONYMOUS: "12 Current Essentials - Physiogel AI Cream | Very Sensitive", 26 May 2012 (2012-05-26), XP055179372, Retrieved from the Internet <URL:https://verysensitive.wordpress.com/2012/05/26/12-current-essentials-physiogel-ai-cream/> [retrieved on 20150325] *
BERGSTROM; SAMUELSSON ET AL., NUTRITION CLASSICS. BIOCHIMICA ET BIOPHYSICA ACTA, vol. 90, 1964, pages 207 - 10

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100024464A1 (it) * 2021-09-23 2023-03-23 Epitech Group S P A N-palmitoil-etanolamide e acido docosaesaenoico per l’uso nel trattamento del disturbo dello spettro autistico e di altre sindromi depressive
EP4154875A1 (en) * 2021-09-23 2023-03-29 EPITECH GROUP S.p.A. N-palmitoylethanolamide and docosahexaenoic acid for use in the treatment of autism spectrum disorder and other depressive syndromes

Also Published As

Publication number Publication date
TW201609084A (zh) 2016-03-16
MA40417A (fr) 2017-06-14
US10149827B2 (en) 2018-12-11
US9962355B2 (en) 2018-05-08
JP2023041806A (ja) 2023-03-24
JP2021004260A (ja) 2021-01-14
EP3177281A1 (en) 2017-06-14
FI3177281T3 (fi) 2024-03-13
IL250271B2 (en) 2023-02-01
ES2976095T3 (es) 2024-07-23
IL250271B (en) 2022-10-01
EP3177281B1 (en) 2023-12-06
TWI727926B (zh) 2021-05-21
CA2957700C (en) 2022-12-13
CN106714792A (zh) 2017-05-24
IL250271A0 (en) 2017-03-30
DK3177281T3 (da) 2024-03-11
US20170224645A1 (en) 2017-08-10
US20180243254A1 (en) 2018-08-30
JP7335475B2 (ja) 2023-08-30
JP2017523230A (ja) 2017-08-17
BR112017002474A2 (pt) 2017-12-05
CA2957700A1 (en) 2016-02-11
JP7118642B2 (ja) 2022-08-16
CO2017001088A2 (es) 2017-04-28

Similar Documents

Publication Publication Date Title
US10149827B2 (en) Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
RU2276975C2 (ru) Терапевтические комбинации жирных кислот
CN103458893B (zh) Sn‑1(3)单酰基甘油酯和脂质吸收
ITMI20130354A1 (it) Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
JPH0369886B2 (enExample)
US20200222476A1 (en) Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
JP2017523230A5 (enExample)
EP0257081A1 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
EP3302451A1 (en) Combination comprising palmitoylethanolamide (pea) and lycopene for use in the treatment of inflammatory diseases
JP5952556B2 (ja) 褥瘡治療剤
BR112017002474B1 (pt) Mistura contendo ácido graxo e palmitoiletanolamida e composição compreendendo tal mistura
ITMI20142077A1 (it) Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie
WO2025075519A1 (en) Preparation and its application in atopic dermatitis in children
JPH08310948A (ja) 抗脱毛症剤
Singer ICU nutrition: Treatment and problem solving Topic 18
RU2019117597A (ru) Пероральные композиции с иммуномодулирующим эффектом в отношении естественных клеток-киллеров
Guarner et al. either by acid hypersecretion (cysteamine-induced duodenal ulcers) or by inflammatory injury (hapten model of granulomatous colitis).
HK1243327B (en) Combination comprising spirulina and palmitoylethanolamide
RU99106551A (ru) Применение арахидоновой кислоты и/или докозагексаеновой кислоты для получения лекарства для лечения диспраксии

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15754028

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 250271

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2957700

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2015754028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015754028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: NC2017/0001088

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 15502316

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2017508099

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017002474

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: NC2017/0001088

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112017002474

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170207

WWR Wipo information: refused in national office

Ref document number: NC2017/0001088

Country of ref document: CO